Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind study of GB221 + docetaxel versus trastuzumab + docetaxel as first-line treatment for HER2-positive metastatic breast cancer
CTR20171510Phase 3Active
- Sponsor
- Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of coprelotamab in breast cancer, sponsored by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology. Started May 2018; status: active.
02
Drugs
coprelotamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20171510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171510.